OR unadjusted | OR adjusted for age, gender and treatment group | |||
---|---|---|---|---|
Estimate (CI) | P-value | Estimate (CI) | P-value | |
Predictors baseline | ||||
Age (years) | 0.94 (0.82 to 1.07) | 0.36 | 0.962 (0.833 to 1.11) | 0.599 |
Male gender | 0.26 (0.073 to 0.96) | 0.043a | 0.25 (0.064 to 0.970) | 0.045a |
BPRS baseline | 1.11 (1.01 to 1.21) | 0.028a | 1.10 (0.997–1.121) | 0.057 |
Days as inpatient 1 year preceding baseline | 0.998 (0.992 to 1.004) | 0.44 | 0.998 (0.992 to 1.004) | 0.496 |
Negative symptoms | 0.889 (0.727–1.088) | 0.253 | 0.855 (0.677–1.080) | 0.19 |
GAF baseline | 0.913 (0.854–0.982) | 0.013a | 0.92 (0.857–0.989) | 0.024a |
Predictors 2 years | ||||
BPRS 2 years | 1.10 (1.02 to 1.19) | 0.013a | 1.1 (1.006 to 1.20) | 0.036a |
Days as inpatient 2 years after baseline | 1.013 (1.002–1.024) | 0.023a | 1.010 (0.999 to 1.022) | 0,082 |
Integrated treatment or Treatment as usual | 0.31 (0.087 to 1.13) | 0.076 | 0.29 (0.073 to 1.14) | 0.077 |
Admitted to hospital the first 2 years after baseline | 8.5 (2.137–33.814) | 0.002a | 10.411 (1.956–55.399) | 0.006a |
Negative symptoms | 0.935 (0.773–1.129) | 0.484 | 0.845 (0.673–1.060) | 0.146 |
GAF | 0.950 (0.912–0.991) | 0.017a | 0.949 (0.907–0.993) | 0.023a |
Compliance medication | 4.286 (0.988–18.586) | 0.052 | 0.097 (0.015–0.607) | 0.013a |
Absence of psychotic relapse | 0.165 (0.045–0.600) | 0.006a | 0.135 (0.029–0.632) | 0.010a |